Karin Jooss
Hoofd Techniek/Wetenschap/O&O bij GRITSTONE BIO, INC.
Vermogen: 561 009 $ op 30-04-2024
Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| J. Wolchko | M | 53 | 17 jaar | |
| Andrew Allen | M | 57 | 9 jaar | |
| William Rastetter | M | 75 | 13 jaar | |
| Shefali Agarwal | M | 50 | 5 jaar | |
| John Mendlein | M | 64 | 17 jaar | |
| Elaine Jones | M | 69 | 5 jaar | |
| Naiyer Rizvi | M | 60 | - | |
| Robert Epstein | M | 58 | 10 jaar | |
| Steve Krognes | M | 55 | 6 jaar | |
| James Cho | M | - | 5 jaar | |
| Yuan Xu | M | 56 | 3 jaar | |
| Clare Fisher | F | 51 | 2 jaar | |
| Bahram Valamehr | M | 47 | 6 jaar | |
| Erin Jones | M | 52 | 8 jaar | |
| Cindy Tahl | F | 51 | 15 jaar | |
| Joseph Echevarria | M | 66 | 9 jaar | |
| George E. MacDougall | M | - | 3 jaar | |
| Helen Hobbs | M | 71 | 13 jaar | |
| Edward Dulac | M | 49 | 4 jaar | |
| Jim Smith | M | 64 | 10 jaar | |
| Lawrence Corey | M | 77 | 2 jaar | |
| Tim Coughlin | M | 57 | 11 jaar | |
| Michael Lee | M | 45 | 6 jaar | |
| Shantanu Narayen | M | 60 | 11 jaar | |
| Bryan Supran | M | - | 8 jaar | |
| Jerome C. Bressi | M | - | 6 jaar | |
| Steve Danehy | M | - | 12 jaar | |
| Jim Beitel | M | - | 7 jaar | |
| Stacy Lea Proctor | F | - | - | |
| Denis Patrick | M | - | 14 jaar | |
| Matthew Hawryluk | M | 46 | 9 jaar | |
| Mikael Dolsten | M | 65 | 15 jaar | |
| Vassiliki Economides | F | 44 | 3 jaar | |
| Wen Bo Wang | M | - | 6 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Jeffrey Kindler | M | 68 | 8 jaar | |
| William Steere | M | 88 | 28 jaar | |
| Amir Nashat | M | 51 | 13 jaar | |
| Amy Schulman | F | 63 | 6 jaar | |
| Sharon Tetlow | F | 64 |
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 4 jaar |
| George A. Lorch | M | 82 | 15 jaar | |
| Nicholas Simon | M | 67 | 6 jaar | |
| Yi Ning Zhao | M | 53 | 8 jaar | |
| Judith Li | F | 40 | 5 jaar | |
| Marc Tessier-Lavigne | M | 64 | 4 jaar | |
| Richard Heyman | M | 66 | 7 jaar | |
| Robert Landry | M | 60 | 4 jaar | |
| Thomas Woiwode | M | 52 | 6 jaar | |
| Olivier Brandicourt | M | 68 | 13 jaar | |
| Peter Svennilson | M | 62 | 4 jaar | |
| Joseph J. Vallner | M | 76 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 7 jaar |
| John Mascotte | M | 84 | 4 jaar | |
| Dana George Mead | M | 88 | 12 jaar | |
| William Herbert Gray | M | 82 | 13 jaar | |
| Robert Hershberg | M | 61 | 4 jaar | |
| John J. Schembri | M | 62 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 3 jaar |
| Michael Brown | M | 83 | 16 jaar | |
| Frances Fergusson | M | 79 | 9 jaar | |
| Robert N. Burt | M | 86 | 11 jaar | |
| Freda Lewis-Hall | M | 69 | 11 jaar | |
| M. Anthony Burns | M | 81 | 25 jaar | |
| Everett Cunningham | M | 57 | 9 jaar | |
| David B. Huang | M | 49 | 3 jaar | |
| John Porter | M | 53 | 5 jaar | |
| François-Maurice Garnier | M | 62 | - | |
| Joann Eisenhart | M | 65 | 12 jaar | |
| Randy Brenner | M | 51 | 15 jaar | |
| Brian Krex | M | 57 | 9 jaar | |
| Cara Cassino | M | 62 | 5 jaar | |
| Michael Bruce | M | - | 12 jaar | |
| Richard Buller | M | 74 | 7 jaar | |
| Feng Guo | M | 54 | 11 jaar | |
| Timothy Sullivan | M | 54 | 2 jaar | |
| Glenn Miles | M | 58 | 4 jaar | |
| Robyn Peters | F | - | 4 jaar | |
| Valerie L. Legagneur | F | 50 | 10 jaar | |
| Susan E. Ward | M | - | 2 jaar | |
| James Wassil | M | 54 | 4 jaar | |
| Margaret McLoughlin | M | 60 | 5 jaar | |
| Peter H. Reinhart | M | - | 6 jaar | |
| Thomas Liquard | M | 51 | 4 jaar | |
| Edmund Harrigan | M | 71 | 12 jaar | |
| Jennifer J. Rhodes | F | 53 | 6 jaar | |
| Charles A. Baker | M | 91 | 19 jaar | |
| Steven Romano | M | 64 | 16 jaar | |
| John Henderson | M | 79 | - | |
| Corey Goodman | M | 72 | 2 jaar | |
| Scott R. Shively | M | 67 | 3 jaar | |
| Angela Rossetti | F | 71 | 5 jaar | |
| Peter Honig | M | 67 | 7 jaar | |
| David Simmons | M | 59 | 16 jaar | |
| David Roth | M | 61 | 4 jaar | |
| John Thompson | M | 57 | 7 jaar | |
| Howard Mayer | M | 61 | 7 jaar | |
| Christine Regan Lindenboom | F | 43 | - | |
| Brenda Mitchell | F | - | - | |
| Anja Guntermann | M | - | 9 jaar | |
| Julie LeChasseur | F | - | 4 jaar | |
| Lillian Mu | F | - | 4 jaar | |
| Michael Pastoor | M | - | 5 jaar | |
| Kimberly Ma | F | - | 3 jaar |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Verenigde Staten | 100 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Karin Jooss
- Persoonlijk netwerk
